With the Moderna (NASDAQ:MRNA) share price blasting up, have the forward-looking markets got it right?

The Moderna (NASDAQ: MRNA) share price is going gangbusters as the world awaits results of its COVID-19 vaccine trial. Let's take a look.

| More on:
small figure representing ASX shares with cape and shield fighting coronavirus

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Moderna Inc (NASDAQ: MRNA) share price went like gangbusters yesterday, overnight Aussie time. The US biotech company's share price leapt 10.8%. And its up another 3.8% in afterhours trading.

This comes as investors eagerly anticipate the outcome of the final analysis of Moderna's promising COVID-19 vaccine trial.

Earlier this month, Moderna joined Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) in a globally exclusive club when the company announced its vaccine looked to be 95% effective in its extensive trial. One which encompassed 30,000 people.

Moderna's share price is now up 62% so far in November, and 468% so far in 2020. At the current share price, Moderna has a market cap of $48 billion.

What does Moderna do?

Based in the United States city of Cambridge, Massachusetts, Moderna is a biotechnology company. The company focuses on developing and discovering new drugs and vaccine technologies based on messenger RNA. Moderna's technology platform inserts synthetic mRNA into human cells.

Why did the Moderna's share price leap 11% overnight?

Moderna's share price has been steadily moving higher on a series of positive announcements from the company.

Among those, the US has committed to buying 100 million doses of its vaccine, mRNA-1273, provided it wins emergency use approval. And it's not just the US.

Japan has agreed to buy 50 million doses, Canada wants 20 million and, in the latest development, the European Commission agreed to buy 80 million doses with an option to double that to 160 million. That agreement remains subject to European approval of the vaccine.

The 10.8% share price leap overnight comes as Moderna expects to release the final data from its expansive trial within the next week. Should the vaccine's efficacy prove to be in the 94.5% range as initially reported, Moderna will then file for emergency use authorisation with the US Food and Drug Administration (FDA).

If it gains approval, Moderna's vaccine could begin mass distribution just as global infection rates are rocketing to new levels. Hence the big share price surge.

Share markets are said to be forward looking. Meaning they anticipate tomorrow's news today.

With more than 588,000 new infections reported on Tuesday, 24 March, and global cases exceeding 60.2 million with 1.4 million fatalities, let's all hope the market's got this one right!

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

three men stand on a winner's podium with medals around their necks with their hands raised in triumph.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the trading week this Friday.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Share Gainers

3 ASX 200 stocks storming higher in this week's sinking market

Investors have sent these three ASX 200 stocks soaring this week. But why?

Read more »

Two smiling work colleagues discuss an investment at their office.
Share Gainers

Why 4DMedical, Develop Global, EOS, and Maas shares are racing higher today

These shares are ending the week on a high. But why?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Up 657% in a year, 4DMedcial shares rocketing another 20% today on big US news

ASX investors can’t get enough of 4DMedical shares today. Let’s see why.

Read more »

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX 200 broke its losing streak to inch higher today.

Read more »

Wife and husband with a laptop on a sofa over the moon at good news.
Consumer Staples & Discretionary Shares

Bapcor shares soar 12% on the appointment of a new CEO

The market’s strong reaction reflects a clear message: investors are ready for a reset.

Read more »

A young woman drinking coffee in a cafe smiles as she checks her phone.
Share Gainers

Why Bapcor, IDP Education, Netwealth, and Ora Banda shares are pushing higher today

These shares are catching the eye with solid gains on Thursday. But why are they rising?

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

This ASX stock is going parabolic, and I think it's still a buy

4DMedical shares are up nearly 500% in 2025, but improving revenue visibility suggests the growth story may not be over.

Read more »